Immune Design Corp. (NASDAQ:IMDZ) – Equities researchers at Leerink Swann increased their Q3 2017 EPS estimates for Immune Design Corp. in a research note issued on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the biotechnology company will earn ($0.67) per share for the quarter, up from their previous forecast of ($0.68). Leerink Swann also issued estimates for Immune Design Corp.’s FY2017 earnings at ($2.40) EPS, FY2018 earnings at ($2.21) EPS, FY2019 earnings at ($2.50) EPS, FY2020 earnings at ($2.42) EPS and FY2021 earnings at ($1.89) EPS.
Several other research firms have also issued reports on IMDZ. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 target price (up from $16.00) on shares of Immune Design Corp. in a report on Friday, May 19th. BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a report on Tuesday, June 6th. Finally, ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $14.50.
Immune Design Corp. (NASDAQ IMDZ) opened at 10.00 on Monday. The stock has a 50 day moving average of $9.78 and a 200 day moving average of $7.11. Immune Design Corp. has a 1-year low of $4.50 and a 1-year high of $13.05. The stock’s market cap is $256.19 million.
Immune Design Corp. (NASDAQ:IMDZ) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.11. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%.
In other Immune Design Corp. news, insider Wayne Gombotz sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $11.43, for a total transaction of $114,300.00. Following the completion of the sale, the insider now directly owns 33,054 shares of the company’s stock, valued at approximately $377,807.22. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lewis W. Coleman acquired 8,000 shares of the business’s stock in a transaction on Friday, July 7th. The shares were bought at an average cost of $9.27 per share, with a total value of $74,160.00. Following the completion of the acquisition, the director now owns 40,000 shares in the company, valued at $370,800. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 30,000 shares of company stock valued at $272,760. Insiders own 42.90% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Immune Design Corp. during the second quarter worth about $117,000. Trexquant Investment LP bought a new stake in shares of Immune Design Corp. during the first quarter worth about $183,000. Rhumbline Advisers raised its stake in shares of Immune Design Corp. by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after buying an additional 6,896 shares during the period. Finally, TIAA CREF Investment Management LLC raised its stake in shares of Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock worth $310,000 after buying an additional 7,236 shares during the period. 50.61% of the stock is owned by institutional investors and hedge funds.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design Corp. and related companies.